Meeting
2011 ASCO Annual Meeting
Phase I feasibility study of intraperitoneal cisplatin and intravenous paclitaxel followed by intraperitoneal paclitaxel in untreated ovarian, fallopian tube, and primary peritoneal carcinoma: Gynecologic Oncology Group study 9921.
Authors
D. S. Dizon
Warren Alpert Medical School of Brown University, Providence, RI
D. S. Dizon , M. Sill , N. S. Gould , S. C. Rubin , S. D. Yamada , R. DeBernardo , R. S. Mannel , E. L. Eisenhauer , L. R. Duska , P. M. Fracasso
Disclaimer
This material on this page is ©2024 American Society of Clinical Oncology, all rights reserved. Licensing available upon request. For more information, please contact licensing@asco.org
Poster Details
Session Type
Poster Session
Session Title
Gynecologic Cancer
Track
Gynecologic Cancer
Sub Track
Ovarian Cancer
Clinical Trial Registration Number
NCT00814086
Citation
J Clin Oncol 29: 2011 (suppl; abstr 5066)
Abstract #
5066
Poster Bd #
17F
Abstract Disclosures
Similar Posters
Poster
2023 ASCO Annual Meeting
Safety and efficacy of PIPAC in ovarian cancer patients with peritoneal metastases: A first-in-US phase I study.
First Author: Rosemary Senguttuvan
Poster
2019 ASCO Annual Meeting
A phase I study of veliparib incorporated into front-line platinum based cheotherpy and bevacizumab in epithelial ovarian cancer (NCT00989651): A GOG/nrg trial.
First Author: Deborah Kay Armstrong
Poster
2017 ASCO Annual Meeting
A phase I dose-escalation study of intraperitoneal (IP) cisplatin, IV/IP paclitaxel, IV bevacizumab, and oral olaparib for newly diagnosed adenxal carcinoma.
First Author: Jason A. Konner
Poster
2012 Gastrointestinal Cancers Symposium
Phase I study of weekly intraperitoneal paclitaxel combined with S-1 and oxaliplatin for gastric cancer with peritoneal metastasis.
First Author: Hironori Ishigami